Caixin
Jan 26, 2022 05:55 AM
TECH

China’s First mRNA Covid Shot Triggers 80%–95% Immune Response

China’s first home-grown mRNA Covid shot triggered immune responses in 80%–95% of subjects in a Phase 1 clinical trial, the sponsors reported.
China’s first home-grown mRNA Covid shot triggered immune responses in 80%–95% of subjects in a Phase 1 clinical trial, the sponsors reported.

China’s first home-grown Covid-19 vaccine using mRNA technology can trigger an immune response in as many as 95% of recipients with no severe adverse reaction reported, according to data from the first stage of clinical trials.

The vaccine, known as ARCoV, is being jointly developed by Walvax Biotechnology Co., Suzhou Abogen Biosciences (300142.SZ) and the PLA Academy of Military Science.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription